We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+41.65%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.17B
AUM Growth
+$2.33B
Cap. Flow
+$258M
Cap. Flow %
4.18%
Top 10 Hldgs %
45.67%
Holding
151
New
35
Increased
25
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$54.2M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$47.1M
3
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$40.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$40.1M
5
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$38.9M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$102M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$53.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$36.9M
4
TBPH icon
Theravance Biopharma
TBPH
+$23.1M
5
NVRO
NEVRO CORP.
NVRO
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 82.05%
2 Financials 0.28%
3 Materials 0.1%
4 Technology 0.1%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UROV
51
DELISTED
Urovant Sciences Ltd.
UROV
$23.3M 0.38%
2,366,831
– –
ADPT icon
52
Adaptive Biotechnologies
ADPT
$3.52B
$23.2M 0.38%
480,000
-15,000
-3% -$547K
CTMX icon
53
CytomX Therapeutics
CTMX
$694M
$21.5M 0.35%
2,577,043
-676,880
-21% -$6.29M
CNCE
54
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$21.4M 0.35%
2,150,641
– –
TPTX
55
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$21.3M 0.35%
329,890
-20,000
-6% -$1.15M
DRNA
56
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$20.3M 0.33%
+800,000
New +$17.2M
SLDB icon
57
Solid Biosciences
SLDB
$800M
$19.8M 0.32%
+449,987
New +$18.7M
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.8M 0.29%
3,481,431
+2,104,142
+153% +$8.77M
MORF
59
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$17.6M 0.28%
650,000
– –
CYPH
60
Cypherpunk Technologies Inc
CYPH
$63.5M
$17.5M 0.28%
847,650
+175,000
+26% +$3.75M
VTRS icon
61
Viatris
VTRS
$20.8B
$16.2M 0.26%
1,004,419
+604,419
+151% +$9.8M
SILK
62
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$16.1M 0.26%
385,100
+180,500
+88% +$6.93M
STOK icon
63
Stoke Therapeutics
STOK
$1.81B
$16M 0.26%
671,978
– –
FULC icon
64
Fulcrum Therapeutics
FULC
$246M
$15.8M 0.26%
894,118
+294,118
+49% +$4.63M
YMAB
65
DELISTED
Y-mAbs Therapeutics
YMAB
$15.4M 0.25%
355,366
-167,114
-32% -$6.32M
ESTA icon
66
Establishment Labs
ESTA
$2.7B
$13.8M 0.22%
736,121
-186,512
-20% -$3.17M
HOLX
67
DELISTED
Hologic
HOLX
$13.1M 0.21%
+230,000
New +$11.3M
ALDX icon
68
Aldeyra Therapeutics
ALDX
$95.3M
$12.9M 0.21%
3,085,458
– –
IMMU
69
DELISTED
Immunomedics Inc
IMMU
$12.8M 0.21%
+362,140
New +$10.6M
ALEC icon
70
Alector
ALEC
$171M
$12.5M 0.2%
511,731
– –
TWST icon
71
Twist Bioscience
TWST
$5.34B
$12.4M 0.2%
272,756
-49,600
-15% -$1.78M
BLU
72
DELISTED
BELLUS Health Inc.
BLU
$11.6M 0.19%
+1,125,000
New +$11.4M
RVMD icon
73
Revolution Medicines
RVMD
$38.6B
$11.1M 0.18%
350,000
– –
PODD icon
74
Insulet
PODD
$11.8B
$10.2M 0.17%
52,733
-30,000
-36% -$5.74M
SCPE.U
75
DELISTED
SC Health Corporation Units, each consisting of one Class A ordinary share, $0.0001 par value, and o
SCPE.U
$10.1M 0.16%
1,000,000
– –
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Perceptive Advisors held 151 positions worth $6.17B, up 61% from $3.84B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors deployed $258M of net new capital in Q2 2020, opening 35 new positions and adding to 25 existing holdings. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 95% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $102M trimmed.

  • Perceptive Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 1,250,000 shares worth $58.1M.
  • Perceptive Advisors added most to Zogenix, Inc. in Q2 2020, an estimated $40.1M increase.
  • Perceptive Advisors's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $102M.
  • Perceptive Advisors fully exited Theravance Biopharma in Q2 2020, selling an estimated $23.1M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $6.17B portfolio in Q2 2020.
  • Perceptive Advisors opened 35 new positions and closed 26 in Q2 2020.
  • Perceptive Advisors's portfolio value rose 61% quarter-over-quarter to $6.17B.

Based on Perceptive Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.